This Article  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (2)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Louis M. Aledort, MD

JAMA. 1981;246(2):157.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Paid plasma donor programs are being criticized, principally on the philosophical grounds that human tissue donations should be freely given and not sold. Philosophically, this argument has merit. But in reality, restricting these programs at this time would be injurious to many patients in the United States and abroad. Restrictions would be particularly damaging to the United States' hemophilia patients.

Hemophiliacs fare far better today then a decade ago, thanks in large part to generous supplies of reasonably priced factor VIII and cryoprecipitate. Factor VIII is mainly supplied from commercial sources. Last year, for example, approximately 90% of the factor VIII produced in the United States came from paid sources.

The widening availability of factor VIII has facilitated home treatment and preventive maintenance, freeing hemophiliacs from the time, cost, and inconvenience of repeated emergency care and hospitalization. Their new freedom has in turn freed medical and nursing staffs to develop . . . [Full Text PDF of this Article]

Author Affiliations
Mount Sinai Medical Center New York

Footnotes
Edited by Lawrence D. Grouse, MD, PhD, Senior Editor.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?